John-Paul Leach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8180115/publications.pdf

Version: 2024-02-01

90 papers 4,259 citations

201575 27 h-index 64 g-index

121 all docs

121 docs citations

times ranked

121

2869 citing authors

#	Article	IF	Citations
1	The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet, The, 2007, 369, 1000-1015.	6.3	873
2	The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet, The, 2007, 369, 1016-1026.	6.3	850
3	Seizure control and treatment in pregnancy: Observations from the EURAP Epilepsy Pregnancy Registry. Neurology, 2006, 66, 354-360.	1.5	313
4	Seizure risk from cavernous or arteriovenous malformations. Neurology, 2011, 76, 1548-1554.	1.5	184
5	Free Radical Activity and Hemostatic Factors in NIDDM Patients With and Without Microalbuminuria. Diabetes, 1992, 41, 909-913.	0.3	116
6	Epilepsy in the UK: Misdiagnosis, mistreatment, and undertreatment?. Seizure: the Journal of the British Epilepsy Association, 2005, 14, 514-520.	0.9	114
7	Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy Journal of Neurology, Neurosurgery and Psychiatry, 1997, 62, 372-376.	0.9	108
8	The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1375-1386.	6.3	104
9	Tiagabine. Lancet, The, 1998, 351, 203-207.	6.3	93
10	The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet, The, 2021, 397, 1363-1374.	6.3	93
11	Plasma Endothelinlike Immunoreactivity Levels in IDDM Patients with Microalbuminuria. Diabetes Care, 1992, 15, 1038-1040.	4.3	89
12	Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Research, 2001, 46, 259-270.	0.8	87
13	Which electroencephalography (EEG) for epilepsy? The relative usefulness of different EEG protocols in patients with possible epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1040-1042.	0.9	77
14	Alcohol and drugs in epilepsy: Pathophysiology, presentation, possibilities, and prevention. Epilepsia, 2012, 53, 48-57.	2.6	72
15	Occupational exposure to organic solvents and long-term nervous system damage detectable by brain imaging, neurophysiology or histopathology. Food and Chemical Toxicology, 2003, 41, 153-187.	1.8	70
16	Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. European Journal of Pharmacology, 1997, 325, 35-40.	1.7	64
17	Determination of gabapentin in plasma by high-performance liquid chromatography. Biomedical Applications, 1996, 681, 421-425.	1.7	59
18	Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes, 1992, 41, 909-913.	0.3	54

#	Article	IF	CITATIONS
19	Neurochemical actions of gabapentin in mouse brain. Epilepsy Research, 1997, 27, 175-180.	0.8	45
20	Common ABCB1 polymorphisms are not associated with multidrug resistance in epilepsy using a gene-wide tagging approach. Pharmacogenetics and Genomics, 2007, 17, 217-220.	0.7	45
21	New antiepileptic drugs—an explosion of activity. Seizure: the Journal of the British Epilepsy Association, 1995, 4, 5-17.	0.9	42
22	Accelerated long-term forgetting in temporal lobe epilepsy: Verbal, nonverbal and autobiographical memory. Epilepsy and Behavior, 2012, 25, 622-630.	0.9	41
23	Synergism with GABAergic drugs in refractory epilepsy. Lancet, The, 1994, 343, 1650.	6.3	40
24	Sodium valproate versus lamotrigine: A randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy. Epilepsy Research, 2007, 75, 122-129.	0.8	37
25	Concentration-Effect Studies with Topiramate on Selected Enzymes and Intermediates of the GABA Shunt. Epilepsia, 2000, 41, S30-S34.	2.6	33
26	Effects of tiagabine and vigabatrin on GABA uptake into primary cultures of rat cortical astrocytes. Seizure: the Journal of the British Epilepsy Association, 1996, 5, 229-234.	0.9	31
27	The legacy of vigabatrin in a regional epilepsy clinic. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 327-329.	0.9	30
28	Polypharmacy with Anticonvulsants. CNS Drugs, 1997, 8, 366-375.	2.7	25
29	Epilepsy and Pregnancy: For healthy pregnancies and happy outcomes. Suggestions for service improvements from the Multispecialty UK Epilepsy Mortality Group. Seizure: the Journal of the British Epilepsy Association, 2017, 50, 67-72.	0.9	23
30	Future Prospects for the Drug Treatment of Epilepsy. CNS Drugs, 2001, 15, 955-968.	2.7	22
31	After sudden unexpected death in epilepsy: Lessons learned and the road forward. Epilepsia, 2016, 57, 46-53.	2.6	22
32	Deliberate overdose with the novel anticonvulsant tiagabine. Seizure: the Journal of the British Epilepsy Association, 1995, 4, 155-157.	0.9	21
33	Mutual Interaction Between Remacemide Hydrochloride and Carbamazepine: Two Drugs with Active Metabolites. Epilepsia, 1996, 37, 1100-1106.	2.6	21
34	Success or failure with antiepileptic drug therapy. Neurology, 2003, 60, 162-163.	1.5	18
35	Asymptomatic pontine myelinolysis. European Journal of Neurology, 2006, 13, 1261-1263.	1.7	18
36	Neurological presentation of Fabry's disease in a 52 year old man. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 340-342.	0.9	17

#	Article	IF	CITATIONS
37	Study is needed of visual field defects associated with any long term antiepileptic drug. BMJ: British Medical Journal, 1998, 317, 206-206.	2.4	16
38	REVIEW Antiepileptic drugs: safety in numbers?. Seizure: the Journal of the British Epilepsy Association, 2000, 9, 170-178.	0.9	15
39	Response to drug treatment in newly diagnosed epilepsy: A pilot study of 1H NMR- and MS-based metabonomic analysis. Epilepsy Research, 2010, 88, 189-195.	0.8	15
40	Neurochemical actions of vigabatrin and tiagabine alone and in combination in mouse cortex. General Pharmacology, 1997, 28, 715-719.	0.7	14
41	Mutual interaction between remacemide hydrochloride and phenytoin. Epilepsy Research, 1997, 26, 381-388.	0.8	14
42	Drug withdrawal in the epilepsy monitoring unit – The patsalos table. Seizure: the Journal of the British Epilepsy Association, 2020, 75, 75-81.	0.9	14
43	Hiding in Plain Sight: Functional Neurological Disorders in the News. Journal of Neuropsychiatry and Clinical Neurosciences, 2019, 31, 361-367.	0.9	13
44	Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe. Epilepsy Research, 2020, 165, 106329.	0.8	13
45	Serial perfusion brain tomographic scans detect reversible focal ischaemia in Rasmussen's encephalitis. Postgraduate Medical Journal, 2000, 76, 33-35.	0.9	12
46	Hypothesis: Multiple sclerosis is caused by three-hits, strictly in order, in genetically susceptible persons. Multiple Sclerosis and Related Disorders, 2018, 24, 157-174.	0.9	12
47	Low serum magnesium and 1â€year mortality in alcohol withdrawal syndrome. European Journal of Clinical Investigation, 2019, 49, e13152.	1.7	12
48	Brainstem encephalitis and acute polyneuropathy associated with hepatitis E infection. BMJ Case Reports, 2017, 2017, bcr-2017-220799.	0.2	12
49	Time to focus on brain tumor-related epilepsy trials. Neuro-Oncology Practice, 2014, 1, 123-133.	1.0	11
50	Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Health Technology Assessment, 2021, 25, 1-134.	1.3	11
51	New variant Creutzfeldt–Jakob disease presenting as localization-related epilepsy. Neurology, 2000, 54, 2188-2188.	1.5	10
52	SUDEP discussions with patients and families. Practical Neurology, 2012, 12, 103-106.	0.5	10
53	Modern management of epilepsy. Clinical Medicine, 2013, 13, 84-86.	0.8	10
54	Treatment of epilepsy – towards precision. F1000Research, 2018, 7, 1932.	0.8	8

#	Article	IF	CITATIONS
55	Measuring differential attainment: a longitudinal analysis of assessment results for 1512 medical students at four Scottish medical schools. BMJ Open, 2021, 11, e046056.	0.8	8
56	Neurochemical actions of the desglycinyl metabolite of remacemide hydrochloride (ARL 12495AA) in mouse brain. British Journal of Pharmacology, 1997, 121, 923-926.	2.7	7
57	Remacemide for drug-resistant localization related epilepsy. The Cochrane Library, 2002, , CD001900.	1.5	7
58	Study protocol for a pragmatic randomised controlled trial comparing the effectiveness and cost-effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of standard and new antiepileptic drugs (SANAD-II). BMJ Open, 2020, 10, e040635.	0.8	6
59	Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients. Seizure: the Journal of the British Epilepsy Association, 1997, 6, 179-184.	0.9	5
60	When the antiepileptic drugs are not working. Practical Neurology, 2009, 9, 27-32.	0.5	5
61	SUDEP, the aftermath: supporting the bereaved. Practical Neurology, 2017, 17, 489-492.	0.5	5
62	Lest we forgive. BMJ: British Medical Journal, 1999, 319, 459-459.	2.4	5
63	Hallervorden and History. New England Journal of Medicine, 2003, 348, 1725-1726.	13.9	4
64	Pseudostatus epilepticus in pregnancy. International Journal of Gynecology and Obstetrics, 2007, 97, 47-47.	1.0	4
65	Refractory status epilepticus in adults admitted to ITU in Glasgow 1995–2013 a longitudinal audit highlighting the need for action for provoked and unprovoked status epilepticus. Seizure: the Journal of the British Epilepsy Association, 2019, 65, 138-143.	0.9	4
66	Managing epilepsy in Ramadan: Guidance for healthcare providers and patients. Epilepsy and Behavior, 2020, 111, 107117.	0.9	4
67	Impact of regulatory safety notices on valproate prescribing and pregnancy outcome among women of child-bearing potential in Scotland: a population-based cohort study. BMJ Open, 2022, 12, e058312.	0.8	4
68	Levetiracetam in the management of epilepsy. British Journal of Hospital Medicine, 2004, 65, 740-744.	0.3	3
69	Neurology liaison services in the acute medical receiving unit. Scottish Medical Journal, 2013, 58, 234-236.	0.7	3
70	Quarantining the <scp>OSCE</scp> : reflections on the Glasgow experience. Clinical Teacher, 2020, 17, 94-97.	0.4	3
71	Epilepsy: time for review. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 87-89.	0.2	2
72	Can a patient-centred approach to epilepsy improve outcomes?. Progress in Neurology and Psychiatry, 2010, 14, 27-32.	0.4	1

#	Article	IF	CITATIONS
73	A new era in acute neurological consultations. European Journal of Neurology, 2010, 17, e26-7.	1.7	1
74	Death in pregnancy: a call for neurological action. Practical Neurology, 2015, 15, 244-245.	0.5	1
75	RETROSPECTIVE STUDY OF STATUS EPILEPTICUS IN ADULTS IN GLASGOW FROM 1996–2013. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.1-e1.	0.9	1
76	The view of the clinician and the scientist on the family experience of sudden epilepsy deaths. Epilepsy and Behavior, 2020, 103, 106679.	0.9	1
77	New Antiepileptic Drugs Revolution or Marketing Spin?. Practical Neurology, 2001, 1, 70-81.	0.5	0
78	Overuse of the EEG. Practical Neurology, 2008, 8, 68-68.	0.5	0
79	Thinking outside of the box. Practical Neurology, 2011, 11, 44-47.	0.5	0
80	INITIAL NEUROLOGICAL ASSESSMENT: A PILOT STUDY OF THE †GLASGOW NEUROSCREEN'. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.169-e2.	0.9	0
81	THE JOY OF TEXT; INTERACTIVE LECTURES IN THE ELECTRONIC AGE. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.175-e2.	0.9	0
82	STATUS EPILEPTICUS INCIDENCE AND PROGNOSIS 1995–2013. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.112-e4.	0.9	0
83	Diagnosis of loss of consciousness: When art meets science. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 495.	0.9	0
84	RECURRENT MILLER FISHER SYNDROME IN ADULTS: A CASE REPORT AND LITERATURE REVIEW. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.29-e1.	0.9	0
85	PO016â€Audit of neurological examinations in acute admissions. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A16.4-A17.	0.9	0
86	PO020â€First case of hev presenting with rhombencephalitis and gbs. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A17.4-A18.	0.9	0
87	Neurological Scottish neologisms. Practical Neurology, 2019, 19, 465-466.	0.5	0
88	Longâ€term mortality of patients admitted to an intensive care unit with seizures: a populationâ€based study. Anaesthesia, 2020, 75, 417-418.	1.8	0
89	Winning hearts and minds: ECG reporting in the first seizure clinic. BMC Cardiovascular Disorders, 2021, 21, 364.	0.7	0
90	Epilepsy and pregnancy: identifying risks. Practical Neurology, 2021, , practneurol-2019-002304.	0.5	0